헤더 로고

• All
• Day 1: March 26 (Thu)
• Day 2: March 27 (Fri)
• Day 3: March 28 (Sat)

Day 3: March 28 (Sat)

• Current Practice and Research in T-cell and NK/T-cell Lymphoma in Japan Motoko Yamaguchi
  Mie University Graduate School of Medicine, Japan CV
• Research Progress of NK/ T-Cell Lymphoma: Experience from China Huangming Hong
  Sichuan Cancer Hospital, China CV
• Clinical and Translational Research in T-cell and NK/T-cell Lymphoma in Korea Seok Jin Kim
  Sungkyunkwan University School of Medicine, Korea CV

Day 3: March 28 (Sat)

• Clonal Evolution from Germline to Malignancy: Timing and Mechanisms Jyoti Nangalia
  University of Cambridge, UK CV
• Inherited Myeloid Malignancies: From Genetic Diagnosis to Clinical Management Marc H.G.P. Raaijmakers
  Erasmus MC Cancer Institute, The Netherlands
• Germline Predisposition Genes in Lymphoid Malignancies Susan L. Slager
  Mayo Clinic, USA

Day 3: March 28 (Sat)

• Immunological Landscape of CML Kyung-Mi Lee
  Korea University College of Medicine, Korea
• Integrating Biomarkers to Predict Response to TKIs Sin Tiong Ong
  Duke-NUS Medical School, Singapore CV
• Drug Combination to Overcome Resistance Delphine Rea
  Hôpital Saint-Louis, France CV

Day 3: March 28 (Sat)

• Vaccination and Infection Prevention Seong Jin Choi
  Seoul National University College of Medicine, Korea CV
• Cardiotoxicity: Risk Assessment and Prevention Hyukjin Park
  Chonnam National University Medical School, Korea CV
• Chemotherapy-induced Peripheral Neuropathy Young Woo Jeon
  College of Medicine, The Catholic University of Korea, Korea

Day 3: March 28 (Sat)

• High-risk Multiple Myeloma in 2026: Early Intervention, MRD-driven Therapy, and Beyond Philippe Moreau
  University Hospital of Nantes, France CV